Phase II trial of recombinant alpha-2b-Interferon and low-dose cyclophosphamide in advanced melanoma and renal cell carcinoma

S. Wadler, Avi Israel Einzig, J. P. Dutcher, N. Ciobanu, Leon C. Landau, P. H. Wiernik

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

The combination of Interferon and low-dose cyclophosphamide synergistically inhibits the growth of human breast cancer xenografts, explanted human non-small cell lung carcinoma, and other experimental tumors. To determine whether this combination would demonstrate clinical efficacy against refractory solid tumors, we used recombinant alpha-2b-Interferon, 10 MU/m2 subcutaneously three times per week, and cyclophosphamide, 25 mg orally twice daily, in 42 patients (25 renal cell carcinoma, 17 melanoma). Two patients were inevaluable due to premature removal from the study. The toxicity profile did not differ substantially from that of Interferon alone with malaise, fatigue, fevers, and chills predominating. Sixteen percent of patients experienced an alteration in mental status. Of 40 patients evaluable for response, there were two partial responders (one renal cell carcinoma, one melanoma) and four minor responders (all renal cell carcinoma). The responder with melanoma had previously failed therapy with dacarbazine (DTIC). Seventeen patients remained stable for a median follow-up of 6 months. We conclude that this regimen is well tolerated; however, the combination of Interferon and low-dose cyclophosphamide used in this way does not appear to be superior to the same dose and schedule of Interferon used alone.

Original languageEnglish (US)
Pages (from-to)55-59
Number of pages5
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume11
Issue number1
DOIs
StatePublished - Jan 1 1988

Fingerprint

interferon alfa-2b
Renal Cell Carcinoma
Cyclophosphamide
Melanoma
Interferons
Dacarbazine
Chills
Heterografts
Non-Small Cell Lung Carcinoma
Fatigue
Neoplasms
Appointments and Schedules
Fever
Breast Neoplasms

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Phase II trial of recombinant alpha-2b-Interferon and low-dose cyclophosphamide in advanced melanoma and renal cell carcinoma. / Wadler, S.; Einzig, Avi Israel; Dutcher, J. P.; Ciobanu, N.; Landau, Leon C.; Wiernik, P. H.

In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 11, No. 1, 01.01.1988, p. 55-59.

Research output: Contribution to journalArticle

@article{26711f5306324c9d9dae0250faa3d357,
title = "Phase II trial of recombinant alpha-2b-Interferon and low-dose cyclophosphamide in advanced melanoma and renal cell carcinoma",
abstract = "The combination of Interferon and low-dose cyclophosphamide synergistically inhibits the growth of human breast cancer xenografts, explanted human non-small cell lung carcinoma, and other experimental tumors. To determine whether this combination would demonstrate clinical efficacy against refractory solid tumors, we used recombinant alpha-2b-Interferon, 10 MU/m2 subcutaneously three times per week, and cyclophosphamide, 25 mg orally twice daily, in 42 patients (25 renal cell carcinoma, 17 melanoma). Two patients were inevaluable due to premature removal from the study. The toxicity profile did not differ substantially from that of Interferon alone with malaise, fatigue, fevers, and chills predominating. Sixteen percent of patients experienced an alteration in mental status. Of 40 patients evaluable for response, there were two partial responders (one renal cell carcinoma, one melanoma) and four minor responders (all renal cell carcinoma). The responder with melanoma had previously failed therapy with dacarbazine (DTIC). Seventeen patients remained stable for a median follow-up of 6 months. We conclude that this regimen is well tolerated; however, the combination of Interferon and low-dose cyclophosphamide used in this way does not appear to be superior to the same dose and schedule of Interferon used alone.",
author = "S. Wadler and Einzig, {Avi Israel} and Dutcher, {J. P.} and N. Ciobanu and Landau, {Leon C.} and Wiernik, {P. H.}",
year = "1988",
month = "1",
day = "1",
doi = "10.1097/00000421-198802000-00012",
language = "English (US)",
volume = "11",
pages = "55--59",
journal = "American Journal of Clinical Oncology",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Phase II trial of recombinant alpha-2b-Interferon and low-dose cyclophosphamide in advanced melanoma and renal cell carcinoma

AU - Wadler, S.

AU - Einzig, Avi Israel

AU - Dutcher, J. P.

AU - Ciobanu, N.

AU - Landau, Leon C.

AU - Wiernik, P. H.

PY - 1988/1/1

Y1 - 1988/1/1

N2 - The combination of Interferon and low-dose cyclophosphamide synergistically inhibits the growth of human breast cancer xenografts, explanted human non-small cell lung carcinoma, and other experimental tumors. To determine whether this combination would demonstrate clinical efficacy against refractory solid tumors, we used recombinant alpha-2b-Interferon, 10 MU/m2 subcutaneously three times per week, and cyclophosphamide, 25 mg orally twice daily, in 42 patients (25 renal cell carcinoma, 17 melanoma). Two patients were inevaluable due to premature removal from the study. The toxicity profile did not differ substantially from that of Interferon alone with malaise, fatigue, fevers, and chills predominating. Sixteen percent of patients experienced an alteration in mental status. Of 40 patients evaluable for response, there were two partial responders (one renal cell carcinoma, one melanoma) and four minor responders (all renal cell carcinoma). The responder with melanoma had previously failed therapy with dacarbazine (DTIC). Seventeen patients remained stable for a median follow-up of 6 months. We conclude that this regimen is well tolerated; however, the combination of Interferon and low-dose cyclophosphamide used in this way does not appear to be superior to the same dose and schedule of Interferon used alone.

AB - The combination of Interferon and low-dose cyclophosphamide synergistically inhibits the growth of human breast cancer xenografts, explanted human non-small cell lung carcinoma, and other experimental tumors. To determine whether this combination would demonstrate clinical efficacy against refractory solid tumors, we used recombinant alpha-2b-Interferon, 10 MU/m2 subcutaneously three times per week, and cyclophosphamide, 25 mg orally twice daily, in 42 patients (25 renal cell carcinoma, 17 melanoma). Two patients were inevaluable due to premature removal from the study. The toxicity profile did not differ substantially from that of Interferon alone with malaise, fatigue, fevers, and chills predominating. Sixteen percent of patients experienced an alteration in mental status. Of 40 patients evaluable for response, there were two partial responders (one renal cell carcinoma, one melanoma) and four minor responders (all renal cell carcinoma). The responder with melanoma had previously failed therapy with dacarbazine (DTIC). Seventeen patients remained stable for a median follow-up of 6 months. We conclude that this regimen is well tolerated; however, the combination of Interferon and low-dose cyclophosphamide used in this way does not appear to be superior to the same dose and schedule of Interferon used alone.

UR - http://www.scopus.com/inward/record.url?scp=0023907013&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023907013&partnerID=8YFLogxK

U2 - 10.1097/00000421-198802000-00012

DO - 10.1097/00000421-198802000-00012

M3 - Article

C2 - 3277375

AN - SCOPUS:0023907013

VL - 11

SP - 55

EP - 59

JO - American Journal of Clinical Oncology

JF - American Journal of Clinical Oncology

SN - 0277-3732

IS - 1

ER -